BACKGROUND: The conserved, fusion-active HA2 glycopolypeptide (HA2) subunit of influenza A hemagglutinin comprises four distinct antigenic sites. Monoclonal antibodies (MAbs) recognizing three of these sites are broadly cross-reactive and protective. OBJECTIVES: This study aimed to establish whether antibodies specific to these three antigenic sites were elicited during a natural influenza infection or by vaccination of humans. METHODS: Forty-five paired acute and convalescent sera from individuals with a confirmed influenza A (subtype H3) infection were examined for the presence of HA2-specific antibodies. The fraction of antibodies specific to three particular antigenic sites (designated IIF4, FC12, and CF2 here) was investigated using competitive enzyme immunoassay. RESULTS: Increased levels of antibodies specific to an ectodomain of HA2 (EHA2: N-terminal residues 23-185 of HA2) were detected in 73% of tested convalescent sera (33/45), while an increased level of antibodies specific to the HA2 fusion peptide (N-terminal residues 1-38) was induced in just 15/45 individuals (33%). Competitive assays confirmed that antibodies specific to the IIF4 epitope (within HA2 residues 125-175) prevailed in 86% (13/15) over those specific to the other two epitopes during infection. However, only a negligible increase in HA2-specific antibodies was detectable following vaccination with a current subunit vaccine. CONCLUSIONS: We observed that the antigenic site localized within N-terminal HA2 residues 125-175 was more immunogenic than that within residues 1-38 (HA2 fusion protein), although both are weak natural immunogens. We suggest that new anti-influenza vaccines should include HA2 (or specific epitopes localized within this glycopolypeptide) to enhance their cross-protective efficacy.
BACKGROUND: The conserved, fusion-active HA2 glycopolypeptide (HA2) subunit of influenza A hemagglutinin comprises four distinct antigenic sites. Monoclonal antibodies (MAbs) recognizing three of these sites are broadly cross-reactive and protective. OBJECTIVES: This study aimed to establish whether antibodies specific to these three antigenic sites were elicited during a natural influenza infection or by vaccination of humans. METHODS: Forty-five paired acute and convalescent sera from individuals with a confirmed influenza A (subtype H3) infection were examined for the presence of HA2-specific antibodies. The fraction of antibodies specific to three particular antigenic sites (designated IIF4, FC12, and CF2 here) was investigated using competitive enzyme immunoassay. RESULTS: Increased levels of antibodies specific to an ectodomain of HA2 (EHA2: N-terminal residues 23-185 of HA2) were detected in 73% of tested convalescent sera (33/45), while an increased level of antibodies specific to the HA2 fusion peptide (N-terminal residues 1-38) was induced in just 15/45 individuals (33%). Competitive assays confirmed that antibodies specific to the IIF4 epitope (within HA2 residues 125-175) prevailed in 86% (13/15) over those specific to the other two epitopes during infection. However, only a negligible increase in HA2-specific antibodies was detectable following vaccination with a current subunit vaccine. CONCLUSIONS: We observed that the antigenic site localized within N-terminal HA2 residues 125-175 was more immunogenic than that within residues 1-38 (HA2 fusion protein), although both are weak natural immunogens. We suggest that new anti-influenza vaccines should include HA2 (or specific epitopes localized within this glycopolypeptide) to enhance their cross-protective efficacy.
Authors: Eva Varecková; Vojtech Mucha; Frantisek Kostolanský; Larisa V Gubareva; Alexander Klimov Journal: Virus Res Date: 2007-11-26 Impact factor: 3.303
Authors: Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit Journal: PLoS One Date: 2008-12-16 Impact factor: 3.240
Authors: Mark Y Sangster; Jane Baer; Felix W Santiago; Theresa Fitzgerald; Natalia A Ilyushina; Aarthi Sundararajan; Alicia D Henn; Florian Krammer; Hongmei Yang; Catherine J Luke; Martin S Zand; Peter F Wright; John J Treanor; David J Topham; Kanta Subbarao Journal: Clin Vaccine Immunol Date: 2013-04-10
Authors: S K Rosendahl Huber; M G M Camps; R H J Jacobi; J Mouthaan; H van Dijken; J van Beek; F Ossendorp; J de Jonge Journal: PLoS One Date: 2015-06-05 Impact factor: 3.240
Authors: Xiao-Song He; Sanae Sasaki; Jane Baer; Surender Khurana; Hana Golding; John J Treanor; David J Topham; Mark Y Sangster; Hong Jin; Cornelia L Dekker; Kanta Subbarao; Harry B Greenberg Journal: J Infect Dis Date: 2012-10-29 Impact factor: 5.226
Authors: X Fan; A M Hashem; Z Chen; C Li; T Doyle; Y Zhang; Y Yi; A Farnsworth; K Xu; Z Li; R He; X Li; J Wang Journal: Mucosal Immunol Date: 2014-07-23 Impact factor: 7.313
Authors: Ahmed O Hassan; Omar Amen; Ekramy E Sayedahmed; Sai V Vemula; Samuel Amoah; Ian York; Shivaprakash Gangappa; Suryaprakash Sambhara; Suresh K Mittal Journal: PLoS One Date: 2017-10-12 Impact factor: 3.240